4-hydroxybutyl phenyl sulfone | 60012-67-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 4-hydroxybutyl phenyl sulfone
• 英文别名: 4-Benzenesulfonylbutan-1-ol；4-(benzenesulfonyl)butan-1-ol
• CAS: 60012-67-1
• 化学式: C₁₀H₁₄O₃S
• 分子量: 214.285
• InChiKey: AOMGVHAVIAGBTG-UHFFFAOYSA-N

物化性质

• 沸点：
  407.8±37.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  14
• 可旋转键数：
  5
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  62.8
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-hydroxybutyl phenyl sulfone 在 重铬酸吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 20.0h， 以24%的产率得到4-(苯磺酰基)丁醛
  参考文献：
  名称：

  Bury, Adrian; Earl, Harold A.; Stirling, Charles J. M., Journal of the Chemical Society. Perkin transactions II, 1987, p. 1281 - 1288

  摘要：

  DOI：
• 作为产物：
  描述：

  [(3-溴丙基)硫基]苯 在 Oxone 、 magnesium 作用下， 以 四氢呋喃 为溶剂， 生成 4-hydroxybutyl phenyl sulfone
  参考文献：
  名称：

  灵性化合物的简便合成

  摘要：

  描述了一种基于向内酯中添加α-磺酰基碳二酮的便捷合成方法。

  DOI：

  10.1016/0040-4039(88)85307-3

文献信息

• Sulfone derivatives as 5-HT7 receptor ligands
  申请人：——

  公开号：US20040229864A1

  公开（公告）日：2004-11-18

  The present invention relates to sulfone derivatives of formula (I): Ar—SO 2 —CR 2 R 3 -L-N(R 1 ) 2 I wherein Ar, L, R 1 , R 2 and R 3 are as defined herein, and pharmaceutically acceptable salts and N-oxides thereof, useful in the treatment of a condition which is susceptible to treatment by modulation of 5-HT 7 receptor activity, such as depression or a sleep disorder.

  本发明涉及式（I）的砜衍生物：Ar—SO2—CR2R3-L-N(R1)2I，其中Ar，L，R1，R2和R3如本文所定义，并且其药用盐和N-氧化物，用于治疗通过调节5-HT7受体活性可治疗的疾病，如抑郁症或睡眠障碍。
• Synthesis of N-monosubstituted S-aminoethyl hydrogen thiosulphates with sulphone substituents
  作者：O. L. Salerni、R. N. Clark、B. E. Smart

  DOI：10.1039/j39660000645

  日期：——

  Three synthetic methods are described which give N-monosubstituted S-aminoethyl hydrogen thiosulphates in which the N-substituent contains a sulphone group.

  三种合成方法中描述了给Ñ单取代的小号，其中氨基乙基氢硫代硫酸盐ñ -取代含有砜基团。
• Organic compounds
  申请人：Novartis AG

  公开号：US08084448B2

  公开（公告）日：2011-12-27

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式为的化合物是蛋白酪氨酸磷酸酶（PTPase）的抑制剂，因此可用于治疗PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖耐受性、糖尿病、高血压和大、小血管缺血性疾病相关的胰岛素抵抗，以及伴随2型糖尿病的情况，包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤、脂质代谢异常和其他表现为胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• ORGANIC COMPOUNDS
  申请人：Neubert Alan

  公开号：US20090181928A1

  公开（公告）日：2009-07-16

  Compounds of the formula are inhibitors of protein tyrosine phosphatases (PTPases) and, thus, may be employed for the treatment of conditions mediated by PTPase activity. The compounds of the present invention may also be employed as inhibitors of other enzymes characterized with a phosphotyrosine binding region such as the SH2 domain. Accordingly, the compounds of formula (I) may be employed for prevention and/or treatment of insulin resistance associated with obesity, glucose intolerance, diabetes mellitus, hypertension and ischemic diseases of the large and small blood vessels, conditions that accompany type-2 diabetes, including hyperlipidemia, hypertriglyceridemia, atherosclerosis, vascular restenosis, irritable bowel syndrome, pancreatitis, adipose cell tumors and carcinomas such as liposarcoma, dyslipidemia, and other disorders where insulin resistance is indicated. In addition, the compounds of the present invention may be employed to treat and/or prevent cancer, osteoporosis, musculoskeletal, neurodegenerative and infectious diseases, and diseases involving inflammation and the immune system.

  公式的化合物是蛋白酪氨酸磷酸酶（PTPases）的抑制剂，因此可用于治疗由PTPase活性介导的疾病。本发明的化合物也可用作其他酶的抑制剂，这些酶具有磷酸酪氨酸结合区域，如SH2结构域。因此，公式（I）的化合物可用于预防和/或治疗与肥胖、葡萄糖不耐受、糖尿病、高血压以及大、小血管缺血性疾病有关的胰岛素抵抗。这些疾病包括高脂血症、高三酰甘油血症、动脉粥样硬化、血管再狭窄、肠易激综合征、胰腺炎、脂肪细胞肿瘤和脂肪肉瘤等癌症，以及其他显示胰岛素抵抗的疾病。此外，本发明的化合物可用于治疗和/或预防癌症、骨质疏松症、肌肉骨骼、神经退行性和传染性疾病，以及涉及炎症和免疫系统的疾病。
• Inexpensive and bench stable diarylmethylium tetrafluoroborates as organocatalysts in the light mediated hydrosulfonylation of unactivated alkenes
  作者：Polyssena Renzi、Emanuele Azzi、Sylvain Ascensio、Stefano Parisotto、Fabrizio Sordello、Francesco Pellegrino、Giovanni Ghigo、Annamaria Deagostino

  DOI：10.1039/d3sc00182b

  日期：——

  Indeed, the photoactive species was proved not to be the diarylcarbenium salt itself, but two intermediates, a stable S–C adduct and an ion couple, that were formed after its interaction with sodium benzenesulfinate. Upon absorbing light, the ion couple could reach an excited state with a charge-transfer character which gave the fundamental sulfonyl radical. A PCET (proton-coupled electron transfer) closes

  在本文中，我们展示了二芳基甲基四氟硼酸盐作为可见光促进未活化烯烃氢磺酰化催化剂的合成潜力。这些稳定且易于在多克规模上制备的盐首次被用作有机催化剂。有趣的是，仅 1 mol% 的催化剂负载量就可以从良好到极好的收率有效地获得砜产品，具有高官能团耐受性和高达 15 mmol 烯烃的可扩展性。此处介绍的实验和计算机理研究揭示了形成关键磺酰基的另一种机制。事实上，光活性物种被证明不是二芳基碳鎓盐本身，而是两个中间体，一个稳定的 S-C 加合物和一个离子对，与苯亚磺酸钠相互作用后形成。吸收光后，离子对可以达到具有电荷转移特性的激发态，从而产生基本的磺酰基。PCET（质子耦合电子转移）关闭重整二芳基碳鎓盐的催化循环。